Sign in Subscribe
Pharmaceutical industry

Curetech Completes Recruitment for Phase II Clinical Trial of Monoclonal Antibody CT-011

Strategic Insights

— 1 min read

Curetech Ltd. has reached a significant milestone in its drug development pipeline by completing the recruitment phase for its Phase II clinical trial of the monoclonal antibody CT-011 for treating metastatic colorectal cancer. The trial, which will involve 171 patients undergoing chemotherapy, is expected to last 18 months, with final results to be received after statistical analysis of the data is completed. This development is particularly notable given the substantial investments made by Clal Biotechnology Industries Ltd. and Teva Pharmaceutical Industries Ltd., which have collectively committed to investing over $56.6 million in Curetech.

Key Takeaways:

  • Curetech has completed recruitment for the Phase II clinical trial of monoclonal antibody CT-011 for the treatment of metastatic colorectal cancer, which will include 171 patients undergoing chemotherapy.
  • The trial will last 18 months, and the final results will be received after the completion of statistical analysis of the data.
  • Curetech is also conducting Phase II clinical trials for the treatment of myeloma (a blood cancer) and large B cell lymphoma.
  • The company has several other ongoing Phase I/II trials, including for non-Hodgkin's lymphoma and nonalcoholic steatohepatitis (NASH), a liver disease.
  • Clal Biotechnology Industries Ltd. owns 37% of Curetech, and Teva Pharmaceutical Industries Ltd. owns 30%, with an option to acquire Curetech for $160 million if the clinical trials are successful.

Statistics:

  • 171 patients will be involved in the Phase II clinical trial of CT-011 for the treatment of metastatic colorectal cancer.
  • The trial is expected to last 18 months.
  • Clal Biotechnology Industries Ltd. has committed to investing an additional $40 million in Curetech, on top of the $16.6 million already invested.
  • Teva Pharmaceutical Industries Ltd. has an option to acquire Curetech for $160 million, contingent on the success of the clinical trials.

Sources:

  • "Curetech Completes Recruitment for Phase II Clinical Trial of Monoclonal Antibody CT-011" by Gali Weinreb, Globes, Tel Aviv, Israel, Feb 20, 2011.

Read more